Main Industry
Biotechnology
Main Product/Service
1. Technology Platform
2. 505(b)(2) NDA
3. High Barrier ANDA
2. 505(b)(2) NDA
3. High Barrier ANDA
The content above was translated by Ai
Founded Year
2014
Unified Business No.
24546157
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,659,819,000 (NT$)
Location of Company
Taiwan
, Tainan City
Exit Status
Emerging Stock Exchange(2016)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Handa Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development of niche portfolios. The company’s business strategy comprises utilizing our Taiwan headquarter as our global R&D center and establishing our presence in the world’s two largest pharmaceutical markets (the US and China).
We specialize in controlled-release technology and products that are difficult to formulate. Our business model includes managing all aspects of the product development process through the submission of its 505(b)(2) New Drug Applications (NDA) and High barrier-Abbreviated New Drug Applications (ANDA) to the United States Food and Drug Administration (FDA).
We specialize in controlled-release technology and products that are difficult to formulate. Our business model includes managing all aspects of the product development process through the submission of its 505(b)(2) New Drug Applications (NDA) and High barrier-Abbreviated New Drug Applications (ANDA) to the United States Food and Drug Administration (FDA).
The content above was translated by Ai
